FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives

The FDA approved Revolution Medicines' daraxonrasib for pancreatic cancer treatment. In clinical trials, the drug extended average survival time for patients with the disease. The approval applies to patients with specific genetic mutations in their pancreatic tumors.

Next story